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G protein-coupled receptor kinase 4 (GRK4) with activating polymorphisms desensitize the natriuric renal tubular D1 dopamine
receptor, and these GRK4 polymorphisms are strongly associated with salt sensitivity and hypertension. Meanwhile, N-
terminal pro-B-type natriuretic peptide (NT-proBNP) may be useful in detecting slight volume expansion. However, relations
between hypertension-related gene polymorphisms including GRK4 and cardiovascular indices such as NT-proBNP are not
clear, especially in healthy subjects. Therefore, various hypertension-related polymorphisms and cardiovascular indices were
analyzed in 97 normotensive, healthy Japanese adults. NT-proBNP levels were signiﬁcantly higher in subjects with two or more
GRK4 polymorphic alleles. Other hypertension-related gene polymorphisms, such as those of renin-angiotensin-aldosterone
system genes, did not correlate with NT-proBNP. There was no signiﬁcant association between any of the hypertension-related
gene polymorphisms and central systolic blood pressure, cardioankle vascular index, augmentation index, plasma aldosterone
concentration, or an oxidative stress marker, urinary 8-OHdG. Normotensive individuals with GRK4 polymorphisms show
increased serum NT-proBNP concentration and may be at a greater risk of developing hypertension and cardiovascular disease.
1.Introduction
Renal tubular dopaminergic system inhibits sodium reab-
sorption from the ﬁltrate and induces sodium excretion
[1]. The dopaminergic action in the kidney is impaired
in essential hypertension [2]d u et oa no v e r a c t i v i t yo fG -
protein-coupled receptor kinase type 4 (GRK4), an enzyme
that desensitizes dopamine D1 receptor (D1R) [1, 3]. Over-
activity of GRK4 is shown to be caused by three activating
variants of GRK4, namely, R65L, A142V, and A486V [2, 4],
inhumans,andwehavepreviouslyreportedthattheseGRK4
gene variants are associated with salt-sensitive and low-renin
hypertension [4].
In addition to GRK4, gene polymorphisms related to the
renin-angiotensin-aldosterone system (RAAS), such as angi-
otensin converting enzyme (ACE), angiotensinogen (AGT),
angiotensin II type 1 receptor (AGTR1), and aldosterone sy-
nthase (CYP11B2) [5], have been reported to be associated
with hypertension.
Many studies attempt to link a certain genotype with hy-
pertensivephenotypebyestablishingadiﬀerenceingenotype
frequency between hypertensive and normotensive patients.
However, hypertension is a complex trait that develops
slowly and latently, being modulated by many overlapping
and counteracting systems. Hence, it is diﬃcult to con-
vincingly establish the causality of gene polymorphisms in2 International Journal of Hypertension
hypertension, unless such gene variant is shown to increase
blood pressure in transgenic animal models [2]. Given this
limitation, it may be beneﬁcial to explore associations be-
tween factors postulated to underlie hypertension, such as
ﬂuid retention, RAAS overactivation or oxidative stress, and
hypertension-related genotypes in those who have not yet
developed hypertension.
N-terminalpro-B-typenatriureticpeptide(NT-proBNP)
is a peptide made by cardiomyocytes during the formation
of brain natriuretic peptide (BNP). NT-proBNP is often
used as a biomarker of cardiac volume and pressure load
[6–8]. Because NT-proBNP as a marker is very sensitive
and dynamic, NT-proBNP may reﬂect mild ﬂuid retention
caused by hypertension-related gene variants.
Another prohypertensive condition postulated to be as-
sociated with many of the gene variants is the over-activation
of the RAAS. The increased activity of the RAAS may
be due to the increased aldosterone production in some
instances [9, 10] and an increase in oxidative stress [11]i n
others. Therefore, urinary 8-hydroxy-2 -deoxyguanosine (8-
OHdG), a marker of oxidative stress, and plasma aldosterone
concentration were also measured in this study.
The present study tested the correlations of hyper-
tension-related gene polymorphisms including GRK4 with
physiological and chemical indices related to hypertension
and atherosclerosis in healthy, normotensive adults.
2. Methods
2.1. Study Subjects. All protocols were carried out with
the approval of Fukushima Medical University Institutional
Review Board. Study participants were recruited Japanese
volunteers with normal blood pressure (<140/90mmHg
at oﬃce or <135/85mmHg at home) as deﬁned by the
Japanese Society of Hypertension Committee for Guide-
lines for the Management of Hypertension [12]w h ow e r e
working in a hospital in Fukushima Prefecture. Those with
cardiovascular disease (subjects receiving regular followup),
chronic kidney disease (estimated glomerular ﬁltration rate
<60mL/min/1.73m2 and/or macroproteinuria), or diabetes
(HbA1c-JDS < 6.5% and/or receiving medical treatment)
were excluded from the study. After providing written
consent, study subjects underwent physical examinations
andlaboratorytestsonurineandblood.Atotalof97subjects
were enrolled into the study.
2.2.PhysiologicalTesting. Cardioanklevascularindex(CAVI)
andankle-brachialindex(ABI)weremeasuredbyVS-1500N
(Fukuda Denshi Co., Ltd. Tokyo, Japan). Augmentation
index (AI) and central systolic blood pressure (cSBP) were
measured by HEM-9000AI (OMRON Corp. Kyoto, Japan).
2.3. Urine and Blood Analyses. Second voided urine after
wakeup was collected for analysis. Urinary electrolytes were
measured to estimate the amount of daily sodium intake
based on the Kawasaki’s formula [13, 14]. Urinary albumin
and 8-OHdG was measured by latex nephelometry and
enzyme-linked immunosorbent assay, respectively. Patient
Table 1: Basic characteristics of the subjects.
Units Mean SD
Female ratio % 74
Age years 44.5 9.8
SBP mmHg 124.4 16.2
DBP mmHg 79.1 12.4
eGFR mL/min./1.73m2 89.3 14.0
HDL-C mg/dL 57.0 14.4
LDL-C mg/dL 106.5 28.3
FBS mg/dL 96.5 10.6
HbA1c % 5.39 0.32
Serum uric acid mg/dL 4.6 1.3
SBP:systolic bloodpressure, DBP:diastolicblood pressure, eGFR: estimated
glomerular ﬁltration rate, FBS: fasting blood sugar. HbA1c is represented as
the National Glycohemoglobin Standardization Program value.
samples for blood analyses were obtained at 8:30 AM after
the patients had rested in the recumbent position for 30
minutes. Routine laboratory analyses were performed in the
hospitallaboratorywithanautomatedmethodusingHitachi
Autoanalyzer7070(HitachiHigh-TechnologiesCorporation,
Tokyo, Japan). Complete blood count was performed using
XT-1800i (Sysmex, Kobe, Japan). Plasma aldosterone con-
centration was measured by radioimmunoassay. Serum NT-
proBNP concentration was measured by electrochemilu-
minescence immunoassay. Urinary albumin and 8-OHdG,
plasma aldosterone concentration, and NT-proBNP were
measured by SRL Inc. (Tokyo, Japan).
2.4. Genotyping. Variants of GRK4 (R65L A142V, and
A486V), AGT M235T, AT1R A1166C, CYP11B2 C-344T, and
PAI-1 4/5G were detected by ﬂuorescence probe melting
curves [4]. AGT A-6G, ACE I/D were genotyped as pre-
viously reported. Detailed protocols have been published
elsewhere [15–18].
2.5. Statistics. Data are given as Mean ± SD. Correlations
between physiological indices and number of GRK4 single
nucleotide polymorphisms (SNPs) are assessed by one-
way factorial ANOVA. Association between systolic blood
pressure and NT-ProBNP levels were analyzed by pearson
product-moment correlation coeﬃcient test. Diﬀerences in
laboratory tests among groups in Table 2 were analyzed by
Cochran-Cox test and one-way factorial ANOVA.
3. Results
3.1. General Characteristics. Of the 97 subjects enrolled, 74%
was female. The mean systolic and diastolic blood pressures
at the oﬃce were 124.4 ± 16.2a n d7 9 .1 ± 12.4mmHg,
respectively. Since subjects with diabetes were excluded from
the study, the average levels of FBS and HbA1c were normal
(Table 1).
3.2. Association between Physiological Indices and the Number
of GRK4 Polymorphisms. CAVI, AI, SBP, and cSBP wereInternational Journal of Hypertension 3
Table 2: Hypertension-related gene polymorphisms and serum NT-proBNP, plasma aldosterone, and urinary 8-OHdG concentration.
NT-proBNP (pg/mL)
ACE II DI DD
46.3 ±4.0 (42) 57.1 ±5.8 (43) 46.0 ±9.6 (12)
AGT A-6G AA AG/GG
50.7 ±4.5 (61) 49.2 ±5.1 (32)
AGT M236T
MM/MT TT
48.1 ±5.2 (29) 47.8 ±4.6 (52)
AGTR1 A1166C AA AC/CC
48.4 ±3.4 (75) 45.4 ±17.8( 7 )
CYP11B2 C-344T CC CT TT
48.7 ±4.9 (46) 51.7 ±5.1 (39) 56.6 ±13.5( 9 )
PAI-1 5G5G 4G5G 4G4G
35.5 ±4.5 (11) 57.2 ±5.0 (44) 49.0 ±5.5 (40)
Aldosterone (pg/mL)
GRK4 01 2 
91.1 ±7.4 (26) 80.2 ±5.4 (40) 88.4 ±8.0 (23)
ACE II DI DD
91.6 ±6.3 (41) 75.7 ±4.5 (43) 89.9 ±10.4 (11)
AGT A-6G AA AG/GG
77.8 ±3.9 (61) 92.2 ±7.3 (32)
AGT M236T
MM/MT TT
77.5 ±5.5 (29) 84.5 ±5.1 (52)
AGTR1 A1166C AA AC/CC
82.5 ±4.1 (75) 78.2 ±9.6( 7 )
CYP11B2 C-344T CC CT TT
76.7 ±4.6 (46) 88.1 ±5.9 (39) 92.9 ±12.9( 9 )
PAI-1 5G5G 4G5G 4G4G
86.9 ± 11.2 (11) 85.8 ±5.8 (44) 78.3 ±4.6 (40)
8-OHdG (ng/mL/g/crea)
GRK4 01 2 
107.5 ±5.0 (23) 95.8 ±4.2 (39) 101.0 ±5.0 (23)
ACE II DI DD
106.7 ±4.2 (38) 98.7 ±3.5 (43) 91.2 ±7.7 (12)
AGT A-6G AA AG/GG
97.6 ±2.9 (59) 105.3 ±5.2 (31)
AGT M236T
MM/MT TT
103.7 ±5.5 (28) 98.3 ±3.1 (50)
AGTR1 A1166C AA AC/CC
100.7 ±3.0 (72) 93.9 ±5.8( 7 )
CYP11B2 C-344T CC CT TT
102.7 ±3.7 (44) 100.1 ±4.4 (39) 91.5 ±4.5( 8 )
PAI-1 5G5G 4G5G 4G4G
88.1 ±8.5 (9) 102.2 ±3.9 (43) 102.2 ±3.9 (39)
Number of subjects in each group is indicated in parenthesis below the genotype. GRK4: G-protein coupled receptor kinase 4, ACE: Angiotensin converting
enzyme, AGT: angiotensinogen, AGTR1: Angiotensin II type 1 receptor, CYP11B2: aldosterone synthase, PAI-1: plasminogen activator inhibitor-1, 8-OHdG:
8-hydroxy-2 -deoxyguanosine. Data are represented by mean ± SE. Cochran-cox test was used for the paired comparison and one-way factorial ANOVA was
applied for multiple comparisons.4 International Journal of Hypertension
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Figure 1: The relationships between number of GRK4 polymorphic alleles GRK4 (R65L, A142V, A486V—LL, VV, VV = 6 alleles) and (a)
cardio-ankle vascular index (CAVI), (b) augmentation index (AI), (c) systolic blood pressure (SBP), and (d) central systolic blood pressure.
measured as physiological indices of atherosclerotic changes.
No signiﬁcant relationships were observed between the
number of GRK4 polymorphisms and CAVI, AI, SBP, or
cSBP (Figure 1).
3.3. Association between NT-proBNP Levels and Number of
GRK4 Polymorphisms. In the subjects who have two or
more GRK4 polymorphic alleles, NT-proBNP levels were
signiﬁcantly higher than those with one or no GRK4
polymorphic allele (41.0 ± 5.0v e r s u s6 0 .2 ± 6.7pg/mL,
P<0.05, Figure 2(a)). This was not due to higher blood
pressure, as there was no association between NT-proBNP
and oﬃce SBP in the healthy normotensives in this study
(Figure 2(b)).
3.4.AssociationbetweentheLevelsofNT-proBNP,Aldosterone,
8-OHdG, and Hypertension-Related Genotypes Other Than
GRK4. Other hypertension-related genotypes, ACE, AGT,
AGTR1, and CYP11B2, were not signiﬁcantly associated
with NT-proBNP concentration (Table 2). Also, none of theInternational Journal of Hypertension 5
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Figure 2: (a) Relationship between the number of GRK4 polymorphic alleles GRK4 (R65L, A142V, A486V—LL, VV, VV = 6a l l e l e s )a n d
NT-proBNP concentration. Number of subjects is indicated in each bar. Subjects with incomplete GRK4 genotyping were not included in
the analysis. ∗P<0.05 versus GRK4 SNP-free subjects. (b) The relationship between systolic blood pressure (Systolic BP) and NT-proBNP
concentration.
hypertension-related polymorphisms examined showed sig-
niﬁcant association with plasma aldosterone concentration
or urinary 8-OHdG, a marker of oxidative stress (Table 2).
4. Discussion
The present study showed for the ﬁrst time that a signiﬁcant
increase in serum NT-proBNP concentration exists in nor-
motensive, healthy subjects harboring hypertension-related
polymorphisms of GRK4, while there was no association
between any of the hypertension-related genotypes studied
and physiological indices (CAVI, AI, SBP, and cSBP), plasma
aldosterone concentration, or an oxidative stress marker,
urinary 8-OHdG.
We have previously reported the association between
GRK4 polymorphisms (R65L, A142V, and A486V) and
salt sensitivity and/or hypertension [19]. In Japanese with
untreated, newly diagnosed hypertension, a genetic model
based on GRK4 R65L, GRK4 A142V, and GRK4 A486V
was 94.4% predictive of salt-sensitive hypertension [4]. Also,
in normotensive, young American twins, individuals who
were homozygous for haplotype 65L-142V-A486 showed a
1.05mmHg steeper increase in SBP per year increase in age
compared with those homozygous for the most common
R65-A142-A486 haplotype [20]. The present study did not
ﬁnd a blood pressure diﬀerence in normotensive, Japanese
adults possibly because of lack of power due to a smaller
sample size. However, the fact that there was a signiﬁcant
increase in serum NT-proBNP concentration among those
with GRK4 polymorphisms suggests that salt-sensitive phe-
notype may be apparent before blood pressure elevation.
Salt sensitivity is associated with an increased mor-
bidity and mortality due to cardiovascular disease even
in normotensive population [21]. In patients with stable
coronary disease, NT-pro-BNP is a better marker of long-
term mortality than conventional cardiovascular risk factors
or the degree of left ventricular systolic dysfunction [22, 23].
There are also reports that NT-proBNP is associated with
unfavorable cardiovascular outcome in patients with left
ventricular hypertrophy [24], geriatric population [25, 26]
or diabetes [27]. To determine if GRK4 polymorphisms and
NT-proBNP can predict future cardiac risks, prospective
studies with larger sample size may be useful.
Physiological indices, CAVI and AI, are both known
to increase with greater number of cardiovascular risk
factors and complications [28–30]. AI may be more sensitive
than CAVI in detecting small diﬀerences in cardiovascular
risk factors [31–33]. Also, estimated central systolic blood
pressure (cSBP) has shown to be better than brachial blood
pressure in assessing atherosclerosis and predicting cardio-
vascular outcome [34]. However, in this relatively young,
normotensive study population, none of the hypertension-
related genotypes correlated with cSBP, CAVI, or AI. The
lack of association in this study may suggest that detectable
atherosclerotic damage or hemodynamic alteration is not
one of the early changes during the development of hyper-
tension.
The major ﬁnding of this study is that NT-proBNP
concentration was slightly but signiﬁcantly elevated in
the normotensive subjects with more hypertension-related
GRK4 polymorphisms. The values of NT-proBNP observed
in the present study fall within the normal range, but there6 International Journal of Hypertension
have been studies that show slight but signiﬁcant changes
with diﬀerent conditions. Heringlake et al. examined the
eﬀects of saline infusion on healthy men and found a signif-
icant elevation of plasma NT-proBNP from approximately
3pmol/L (25pg/mL) to 7pmol/L (59pg/mL) 8 hours after
the infusion [35]. Even though the diﬀerence in the values
of NT-proBNP is relatively small, the diagnostic beneﬁt may
still be apparent.
It is notable that among the various hypertension-
related gene polymorphisms studied, only GRK4 showed
a signiﬁcant correlation with serum NT-proBNP concen-
tration. This ﬁnding is in accordance with the proposed
mechanism of association between GRK4 and hypertension,
as polymorphic GRK4 has been shown to increase D1R
phosphorylation, decrease cAMP response to dopamine in
renaltubularcells,andimpairnatriuresis[2,4],whichwould
lead to sodium and ﬂuid retention.
Another ﬁnding from this study is that none of the
hypertension-related gene polymorphisms were associated
with plasma aldosterone concentration or urinary 8-OHdG.
An increase in aldosterone production is postulated to be a
mechanistic link between some RAS-related polymorphisms
and hypertension [10, 36], and oxidative stress is considered
as an important factor in hypertension involving over-active
RAAS [37]. However, at least in this study population, no
signiﬁcantdiﬀerencecouldbedetectedinplasmaaldosterone
concentration or urinary 8-OHdG by diﬀerent genotypes.
An important limitation of this study is that the majority
(74%) of study subjects were female, reﬂecting the high
female ratio of hospital workers in Japan. As such, some of
the ﬁndings may not be directly applicable to the general
population.
In conclusion, GRK4 polymorphisms have a close rela-
tionship with serum NT-proBNP concentration, which may
reﬂect ﬂuid retention and increased cardiac load. GRK4
may be a potential target to screen for the risk of future
hypertension and cardiovascular disease so that lifestyle
modiﬁcationssuchassaltrestrictioncanbechosenbyat-risk
subjects to prevent future adverse events.
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